William J. Chapin

William J. Chapin

Auto-generated profile, based on publicly available information

William J. Chapin

Department of Medicine, Division of Hematology and Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
MLMeiyan Li
Meiyan Li
GLGong Lan
Gong Lan
WCWilliam J. Chapin
William J. Chapin
MZMin Zhu
Min Zhu
Purpose.: To determine vision-related quality of life (QoL) measured with the National Eye Institute Visual Function Questionnaire (NEI-VFQ) and the Ocular Surface Disease Index (OSDI) in dry eye patients, and establish potential correlations with the Zung Self Rating Anxiety Scales (SAS), the Zung Self Rating Depression Scales (SDS), ocular surface parameters, and sociodemographic measures. Methods.: The comparative study included 87 dry eye patients and 71 healthy volunteers who visited the department of ophthalmology, Eye and Ear Nose and Throat (EENT) Hospital of Fudan University, Shanghai, China, between June 2009 and December 2009. Surveys were administered to participants to evaluate their sociodemographic characteristics and disease-related factors. Data collected from the NEI-VFQ and OSDI survey instruments were analyzed to identify potential differences between the dry eye group and the control group. Correlations with sociodemographic characteristics, clinical parameters, and psychological status were evaluated. Results.: Compared with the control group, our patient group had lower (worse) NEI-VFQ scores for the subscales of general health, general vision, ocular pain, short distance vision activities, long distance vision activities, vision related social function, vision related mental health, vision related role difficulties, vision related dependency, and driving (all P < 0.05), and higher (worse) OSDI composite and subscale scores of ocular symptoms, vision-related function, and environmental triggers (all P < 0.001). Significant correlations were found between QoL scores and patient anxiety and depression levels. Conclusions.: Vision-related QoL in dry eye patients was impaired and was correlated with anxiety and depression, further implicating this condition as an important public health problem deserving increased attention and resources.

21 December 2010 in Current Eye Research
Verified
Journal Article
Closed access
PDF file
MLMeiyan Li
Meiyan Li
GLGong Lan
Gong Lan
XSXinghuai Sun
Xinghuai Sun
WCWilliam J. Chapin
William J. Chapin
Purpose: This study aimed to determine whether patients with dry eye syndrome [DES] have more symptoms of anxiety and depression than controls without DES. Methods: In this case-control study, the sample consisted of 89 DES subjects (13 diagnosed with Sjögren’s syndrome [SS]) and 73 control subjects. Each subject was diagnosed as having DES or was chosen as a control subject by an ophthalmologist. The Zung Self Rating Anxiety Scales (SAS), Zung Self Rating Depression Scales (SDS), and Ocular Surface Disease Index (OSDI) were administered to all subjects. Scores of SAS and SDS, measuring level of anxiety and depression symptoms, were compared between the DES group and the control group. Correlations with other health status measures were conducted. Results: The SAS and SDS scores of the DES group were significantly higher than the control group (P < 0.001, P < 0.001). The prevalence of DES subjects with anxiety or depression symptoms was significantly higher than in the control group (P = 0.003, P < 0.001). In the DES group, SAS scores were found to be correlated with OSDI and educational level. SDS scores were found to be correlated with OSDI. Neither SAS nor SDS scores were correlated with age, sex, household income, tear break up time (BUT), Schirmer Test 1 (S1T), corneal fluorescein staining (FL), or visual acuity. Conclusion: Anxiety and depression are correlated with DES, demonstrating that DES is an important public health problem that merits increased attention and research.

13 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJeremy T-H Chang
Jeremy T-H Chang
FWFan Wang
Fan Wang
WCWilliam Chapin
William Chapin
RHR. Stephanie Huang
R. Stephanie Huang
Breast cancer is the second-most common cancer and second-leading cause of cancer mortality in American women. The dysregulation of microRNAs (miRNAs) plays a key role in almost all cancers, including breast cancer. We comprehensively analyzed miRNA expression, global gene expression, and patient survival from the Cancer Genomes Atlas (TCGA) to identify clinically relevant miRNAs and their potential gene targets in breast tumors. In our analysis, we found that increased expression of 12 mature miRNAs—hsa-miR-320a, hsa-miR-361-5p, hsa-miR-103a-3p, hsa-miR-21-5p, hsa-miR-374b-5p, hsa-miR-140-3p, hsa-miR-25-3p, hsa-miR-651-5p, hsa-miR-200c-3p, hsa-miR-30a-5p, hsa-miR-30c-5p, and hsa-let-7i-5p —each predicted improved breast cancer survival. Of the 12 miRNAs, miR-320a, miR-361-5p, miR-21-5p, miR-103a-3p were selected for further analysis. By correlating global gene expression with miRNA expression and then employing miRNA target prediction analysis, we suggest that the four miRNAs may exert protective phenotypes by targeting breast oncogenes that contribute to patient survival. We propose that miR-320a targets the survival-associated genes RAD51, RRP1B, and TDG; miR-361-5p targets ARCN1; and miR-21-5p targets MSH2, RMND5A, STAG2, and UBE2D3. The results of our stringent bioinformatics approach for identifying clinically relevant miRNAs and their targets indicate that miR-320a, miR-361-5p, and miR-21-5p may contribute to breast cancer survival.

22 March 2010 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MHMatthew R. Hoffman
Matthew R. Hoffman
RWRachel E. Witt
Rachel E. Witt
WCWilliam J. Chapin
William J. Chapin
TMTimothy M. McCulloch
Timothy M. McCulloch
JJJack Jiang
Jack Jiang

1 January 2010 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
GLGong Lan
Gong Lan
XSXinghuai Sun
Xinghuai Sun
WCWilliam J. Chapin
William J. Chapin

2 June 2022 in Cancer Medicine
Verified
Journal Article
Open access
WCWilliam J. Chapin
William J. Chapin
WHWei-Ting Hwang
Wei-Ting Hwang
TKThomas B. Karasic
Thomas B. Karasic
AMAnne Marie McCarthy
Anne Marie McCarthy
DKDavid Edward Kaplan
David Edward Kaplan
Background: Patients with decompensated cirrhosis are excluded or underrepresented in clinical trials of systemic therapies for hepatocellular carcinoma (HCC) and comparisons of available therapies are lacking. We aimed to compare overall survival for patients with HCC and Child‐Pugh B cirrhosis treated with nivolumab or sorafenib as first systemic treatment.Methods: We performed a retrospective cohort study in patients with HCC and Child‐Pugh B cirrhosis treated at Veterans Affairs medical centers to compare overall survival, adverse events, and reason for discontinuation of therapy between patients treated with nivolumab or sorafenib as first systemic treatment. All statistical tests were 2‐sided.Results: Of those meeting inclusion criteria, 431 patients were treated with sorafenib and 79 with nivolumab. Median OS was 4.0 months (95% CI 3.5–4.8) in the sorafenib cohort and 5.0 months (95% CI 3.3–6.8) in the nivolumab cohort. In the multivariable Cox proportional hazards model, nivolumab was associated with a significantly reduced hazard of death compared to sorafenib (HR 0.69; 95% CI 0.52–0.91; p = 0.008). In a secondary analysis using propensity score methods, results did not reach statistical significance (HR 0.77; 95% CI 0.55–1.06; p = 0.11). Treatment was discontinued due to toxicity in 12% of patients receiving nivolumab compared to 36% receiving sorafenib (p = 0.001).Conclusion: In patients with HCC and Child‐Pugh B cirrhosis, nivolumab treatment may be associated with improved overall survival and improved tolerability compared to sorafenib and should be considered for the first systemic treatment in this population.